Lucid Diagnostics ( (LUCD) ) just unveiled an announcement.
On March 5, 2025, Lucid Diagnostics Inc. announced the closing of its registered direct offering, raising approximately $15.3 million through the sale of 13,939,331 shares of common stock at $1.10 per share. The net proceeds, estimated at $14.5 million after expenses, will be used for working capital and general corporate purposes, potentially strengthening the company’s financial position and supporting its operations in the cancer prevention diagnostics industry.
More about Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer. Lucid offers the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device, which are designed for early detection of esophageal precancer in at-risk patients.
YTD Price Performance: 64.56%
Average Trading Volume: 536,008
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $77.15M
See more insights into LUCD stock on TipRanks’ Stock Analysis page.